Skip to main content
Top
Published in: Infectious Diseases and Therapy 1/2017

Open Access 01-03-2017 | Review

Infections in Cancer Patients with Solid Tumors: A Review

Author: Kenneth V. I. Rolston

Published in: Infectious Diseases and Therapy | Issue 1/2017

Login to get access

Abstract

Solid tumors are much more common than hematologic malignancies. Although severe and prolonged neutropenia is uncommon, several factors increase the risk of infection in patients with solid tumors, and the presence of multiple risk factors in the same patient is not uncommon. These include obstruction (most often caused by progression of the tumor), disruption of natural anatomic barriers such as the skin and mucosal surfaces, and treatment-related factors such as chemotherapy, radiation, diagnostic and/or therapeutic surgical procedures, and the increasing use of medical devices such as various catheters, stents, and prostheses. Common sites of infection include the skin and skin structures (including surgical site infections), the bloodstream (including infections associated with central venous catheters), the lungs, the hepato-biliary and intestinal tracts, and the urinary tract, and include distinct clinical syndromes such as post-obstructive pneumonia, obstructive uropathy, and neutropenic enterocolitis. The epidemiology of most of these infections is changing with resistant organisms [MRSA, Pseudomonas aeruginosa, extended spectrum beta-lactamase (ESBL)-producing organisms] being isolated more often than in the past. Polymicrobial infections now predominate when deep tissue sites are involved. Conservative management of most of these infections (antibiotics, fluid and electrolyte replacement, bowel rest when needed) is generally effective, with surgical intervention being reserved for the drainage of deep abscesses, or to deal with complications such as intestinal obstruction or hemorrhage. Infected prostheses often need to be removed. Reactivation of certain viral infections (HBV, HCV, and occasionally CMV) has become an important issue, and screening, prevention and treatment strategies are being developed. Infection prevention, infection control, and antimicrobial stewardship are important strategies in the overall management of infections in patients with solid tumors. Occasionally, infections mimic solid tumors and cause diagnostic and therapeutic challenges.
Literature
2.
go back to reference Chizuka A, Suda M, Shibata T, et al. Difference between hematological malignancy and solid tumor research articles published in four major medical journals. Leukemia. 2006;20:1655–7.CrossRef Chizuka A, Suda M, Shibata T, et al. Difference between hematological malignancy and solid tumor research articles published in four major medical journals. Leukemia. 2006;20:1655–7.CrossRef
3.
go back to reference Avritscher EB, Cooksley CD, Rolston KV, et al. Serious postoperative infections following resection of common solid tumors: outcomes, costs, and impact of hospital surgical volume. Support Care Cancer. 2014;22:527–35.CrossRefPubMed Avritscher EB, Cooksley CD, Rolston KV, et al. Serious postoperative infections following resection of common solid tumors: outcomes, costs, and impact of hospital surgical volume. Support Care Cancer. 2014;22:527–35.CrossRefPubMed
5.
go back to reference Tverdek FP, Rolston KV, Chemaly RF. Antimicrobial stewardship in patients with cancer. Pharmacotherapy. 2012;32:722–34.CrossRefPubMed Tverdek FP, Rolston KV, Chemaly RF. Antimicrobial stewardship in patients with cancer. Pharmacotherapy. 2012;32:722–34.CrossRefPubMed
6.
go back to reference Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–51.CrossRefPubMed Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–51.CrossRefPubMed
7.
go back to reference Kern WV. Risk assessment and treatment of low-risk patients with febrile neutropenia. Clin Infect Dis. 2006;42:533–40.CrossRefPubMed Kern WV. Risk assessment and treatment of low-risk patients with febrile neutropenia. Clin Infect Dis. 2006;42:533–40.CrossRefPubMed
8.
go back to reference Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52:e56–93.CrossRefPubMed Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52:e56–93.CrossRefPubMed
9.
go back to reference Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31:794–810.CrossRefPubMed Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31:794–810.CrossRefPubMed
10.
go back to reference Rolston KV. New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin Infect Dis. 1999;29:515–21.CrossRefPubMed Rolston KV. New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin Infect Dis. 1999;29:515–21.CrossRefPubMed
11.
go back to reference Virizuela JA, Carratalà J, Aguado JM, et al. Management of infection and febrile neutropenia in patients with solid cancer. Clin Transl Oncol. 2016;18:557–70.CrossRefPubMed Virizuela JA, Carratalà J, Aguado JM, et al. Management of infection and febrile neutropenia in patients with solid cancer. Clin Transl Oncol. 2016;18:557–70.CrossRefPubMed
12.
go back to reference Rolston KV, Mihu C, Tarrand JJ. Current microbiology of percutaneous endoscopic gastrostomy tube (PEG tube) insertion site infections in patients with cancer. Support Care Cancer. 2011;19:1267–71.CrossRefPubMed Rolston KV, Mihu C, Tarrand JJ. Current microbiology of percutaneous endoscopic gastrostomy tube (PEG tube) insertion site infections in patients with cancer. Support Care Cancer. 2011;19:1267–71.CrossRefPubMed
13.
go back to reference Abers MS, Sandvall BP, Sampath R, et al. Postobstructive pneumonia: an underdescribed syndrome. Clin Infect Dis. 2016;62:957–61.CrossRefPubMed Abers MS, Sandvall BP, Sampath R, et al. Postobstructive pneumonia: an underdescribed syndrome. Clin Infect Dis. 2016;62:957–61.CrossRefPubMed
14.
15.
go back to reference Bin Nafisah S, Ahmad M. Ommaya reservoir infection rate: a 6-year retrospective cohort study of Ommaya reservoir in pediatrics. Childs Nerv Syst. 2015;31:29–36.CrossRefPubMed Bin Nafisah S, Ahmad M. Ommaya reservoir infection rate: a 6-year retrospective cohort study of Ommaya reservoir in pediatrics. Childs Nerv Syst. 2015;31:29–36.CrossRefPubMed
16.
go back to reference Bahu R, Chaftari AM, Hachem RY, et al. Nephrostomy tube related pyelonephritis in patients with cancer: epidemiology, infection rate and risk factors. J Urol. 2013;189:130–5.CrossRefPubMed Bahu R, Chaftari AM, Hachem RY, et al. Nephrostomy tube related pyelonephritis in patients with cancer: epidemiology, infection rate and risk factors. J Urol. 2013;189:130–5.CrossRefPubMed
17.
go back to reference Rolston KV, Nesher L, Tarrand JT. Current microbiology of surgical site infections in patients with cancer: a retrospective review. Infect Dis Ther. 2014;3:245–56.CrossRefPubMedPubMedCentral Rolston KV, Nesher L, Tarrand JT. Current microbiology of surgical site infections in patients with cancer: a retrospective review. Infect Dis Ther. 2014;3:245–56.CrossRefPubMedPubMedCentral
18.
go back to reference Marín M, Gudiol C, Garcia-Vidal C, Ardanuy C, Carratalà J. Bloodstream infections in patients with solid tumors: epidemiology, antibiotic therapy, and outcomes in 528 episodes in a single cancer center. Medicine (Baltimore). 2014;93:143–9.CrossRef Marín M, Gudiol C, Garcia-Vidal C, Ardanuy C, Carratalà J. Bloodstream infections in patients with solid tumors: epidemiology, antibiotic therapy, and outcomes in 528 episodes in a single cancer center. Medicine (Baltimore). 2014;93:143–9.CrossRef
19.
go back to reference Rolston KV. The spectrum of pulmonary infections in cancer patients. Curr Opin Oncol. 2001;13:218–23.CrossRefPubMed Rolston KV. The spectrum of pulmonary infections in cancer patients. Curr Opin Oncol. 2001;13:218–23.CrossRefPubMed
20.
go back to reference Badgwell BD, Cormier JN, Wray CJ, et al. Challenges in surgical management of abdominal pain in the neutropenic cancer patient. Ann Surg. 2008;248:104–9.CrossRefPubMed Badgwell BD, Cormier JN, Wray CJ, et al. Challenges in surgical management of abdominal pain in the neutropenic cancer patient. Ann Surg. 2008;248:104–9.CrossRefPubMed
21.
go back to reference Yapici O, Gunseren F, Yapici H, Merdin A, Yaylali Ü, Merdin FA. Evaluation of febrile neutropenic episodes in adult patients with solid tumors. Mol Clin Oncol. 2016;4:379–82.PubMed Yapici O, Gunseren F, Yapici H, Merdin A, Yaylali Ü, Merdin FA. Evaluation of febrile neutropenic episodes in adult patients with solid tumors. Mol Clin Oncol. 2016;4:379–82.PubMed
22.
go back to reference Marin M, Gudiol C, Ardanuy C, et al. Bloodstream infections in neutropenic patients with cancer: differences between patients with haematological malignancies and solid tumours. J Infect. 2014;69:417–23.CrossRefPubMed Marin M, Gudiol C, Ardanuy C, et al. Bloodstream infections in neutropenic patients with cancer: differences between patients with haematological malignancies and solid tumours. J Infect. 2014;69:417–23.CrossRefPubMed
23.
go back to reference Rolston KV, Kontoyiannis DP, Yadegarynia D, Raad II. Nonfermentative gram-negative bacilli in cancer patients: increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones. Diagn Microbiol Infect Dis. 2005;51:215–8.CrossRefPubMed Rolston KV, Kontoyiannis DP, Yadegarynia D, Raad II. Nonfermentative gram-negative bacilli in cancer patients: increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones. Diagn Microbiol Infect Dis. 2005;51:215–8.CrossRefPubMed
24.
go back to reference Torres A, Ferrer M. Editorial Commentary: Distinguishing postobstructive lung infection from community-acquired pneumonia. Clin Infect Dis. 2016;62:962–3.CrossRefPubMed Torres A, Ferrer M. Editorial Commentary: Distinguishing postobstructive lung infection from community-acquired pneumonia. Clin Infect Dis. 2016;62:962–3.CrossRefPubMed
25.
go back to reference Hsu-Kim C, Hoag JB, Cheng GS, Lund ME. The microbiology of postobstructive pneumonia in lung cancer patients. J Bronchol Interv Pulmonol. 2013;20:266–70.CrossRef Hsu-Kim C, Hoag JB, Cheng GS, Lund ME. The microbiology of postobstructive pneumonia in lung cancer patients. J Bronchol Interv Pulmonol. 2013;20:266–70.CrossRef
26.
go back to reference Rolston KV, Bodey GP, Safdar A. Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis. 2007;45:228–33.CrossRefPubMed Rolston KV, Bodey GP, Safdar A. Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis. 2007;45:228–33.CrossRefPubMed
28.
go back to reference de Aquino Gorayeb MM, Gregório MG, de Oliveira EQ, Aisen S, Carvalho HA. High-dose-rate brachytherapy in symptom palliation due to malignant endobronchial obstruction: a quantitative assessment. Brachytherapy. 2013;12:471–8.CrossRefPubMed de Aquino Gorayeb MM, Gregório MG, de Oliveira EQ, Aisen S, Carvalho HA. High-dose-rate brachytherapy in symptom palliation due to malignant endobronchial obstruction: a quantitative assessment. Brachytherapy. 2013;12:471–8.CrossRefPubMed
29.
go back to reference Barr SP, Topps AR, Barnes NL, et al. Infection prevention in breast implant surgery—a review of the surgical evidence, guidelines and a checklist. Eur J Surg Oncol. 2016;42:591–603.CrossRefPubMed Barr SP, Topps AR, Barnes NL, et al. Infection prevention in breast implant surgery—a review of the surgical evidence, guidelines and a checklist. Eur J Surg Oncol. 2016;42:591–603.CrossRefPubMed
30.
go back to reference Brand JS, Colzani E, Johansson AL, et al. Infection-related hospitalizations in breast cancer patients: risk and impact on prognosis. J Infect. 2016;72:650–8.CrossRefPubMed Brand JS, Colzani E, Johansson AL, et al. Infection-related hospitalizations in breast cancer patients: risk and impact on prognosis. J Infect. 2016;72:650–8.CrossRefPubMed
31.
go back to reference Quinn TT, Miller GS, Rostek M, Cabalag MS, Rozen WM, Hunter-Smith DJ. Prosthetic breast reconstruction: indications and update. Gland Surg. 2016;5:174–86.PubMedPubMedCentral Quinn TT, Miller GS, Rostek M, Cabalag MS, Rozen WM, Hunter-Smith DJ. Prosthetic breast reconstruction: indications and update. Gland Surg. 2016;5:174–86.PubMedPubMedCentral
32.
go back to reference Nahabedian MY, Tsangaris T, Momen B, Manson PN. Infectious complications following breast reconstruction with expanders and implants. Plast Reconstr Surg. 2003;112:467–76.CrossRefPubMed Nahabedian MY, Tsangaris T, Momen B, Manson PN. Infectious complications following breast reconstruction with expanders and implants. Plast Reconstr Surg. 2003;112:467–76.CrossRefPubMed
33.
go back to reference Cordeiro PG, McCarthy CM. A single surgeon’s 12-year experience with tissue expander/implant breast reconstruction: part II. An analysis of long-term complications, aesthetic outcomes, and patient satisfaction. Plast Reconstr Surg. 2006;118:832–9.CrossRefPubMed Cordeiro PG, McCarthy CM. A single surgeon’s 12-year experience with tissue expander/implant breast reconstruction: part II. An analysis of long-term complications, aesthetic outcomes, and patient satisfaction. Plast Reconstr Surg. 2006;118:832–9.CrossRefPubMed
34.
go back to reference Francis SH, Ruberg RL, Stevenson KB, et al. Independent risk factors for infection in tissue expander breast reconstruction. Plast Reconstr Surg. 2009;124:1790–6.CrossRefPubMed Francis SH, Ruberg RL, Stevenson KB, et al. Independent risk factors for infection in tissue expander breast reconstruction. Plast Reconstr Surg. 2009;124:1790–6.CrossRefPubMed
35.
go back to reference Cordeiro PG, Pusic AL, Disa JJ, McCormick B, VanZee K. Irradiation after immediate tissue expander/implant breast reconstruction: outcomes, complications, aesthetic results, and satisfaction among 156 patients. Plast Reconstr Surg. 2004;113:877–81.CrossRefPubMed Cordeiro PG, Pusic AL, Disa JJ, McCormick B, VanZee K. Irradiation after immediate tissue expander/implant breast reconstruction: outcomes, complications, aesthetic results, and satisfaction among 156 patients. Plast Reconstr Surg. 2004;113:877–81.CrossRefPubMed
36.
go back to reference Epstein M, Silverstein M, Lin K, et al. Acute and chronic complications in breast cancer patients treated with intraoperative radiation therapy. Ann Surg Oncol. 2016;23:3304–9.CrossRefPubMed Epstein M, Silverstein M, Lin K, et al. Acute and chronic complications in breast cancer patients treated with intraoperative radiation therapy. Ann Surg Oncol. 2016;23:3304–9.CrossRefPubMed
37.
go back to reference Huo J, Smith BD, Giordano SH, Reece GP, Shih YC. Post-mastectomy breast reconstruction and its subsequent complications: a comparison between obese and non-obese women with breast cancer. Breast Cancer Res Treat. 2016;157:373–83.CrossRefPubMed Huo J, Smith BD, Giordano SH, Reece GP, Shih YC. Post-mastectomy breast reconstruction and its subsequent complications: a comparison between obese and non-obese women with breast cancer. Breast Cancer Res Treat. 2016;157:373–83.CrossRefPubMed
38.
go back to reference Seng P, Bayle S, Alliez A, Romain F, Casanova D, Stein A. The microbial epidemiology of breast implant infections in a regional referral centre for plastic and reconstructive surgery in the south of France. Int J Infect Dis. 2015;35:62–6.CrossRefPubMed Seng P, Bayle S, Alliez A, Romain F, Casanova D, Stein A. The microbial epidemiology of breast implant infections in a regional referral centre for plastic and reconstructive surgery in the south of France. Int J Infect Dis. 2015;35:62–6.CrossRefPubMed
39.
go back to reference Rolston KV, Nesher L, Tarrand JT. Current microbiology of surgical site infections in patients with cancer: a retrospective review. Infect Dis Ther. 2014;3:245–256. Rolston KV, Nesher L, Tarrand JT. Current microbiology of surgical site infections in patients with cancer: a retrospective review. Infect Dis Ther. 2014;3:245–256.
40.
go back to reference McCullough MC, Chu CK, Duggal CS, Losken A, Carlson GW. Antibiotic prophylaxis and resistance in surgical site infection after immediate tissue expander reconstruction of the breast. Ann Plast Surg. 2014;73:1–5. McCullough MC, Chu CK, Duggal CS, Losken A, Carlson GW. Antibiotic prophylaxis and resistance in surgical site infection after immediate tissue expander reconstruction of the breast. Ann Plast Surg. 2014;73:1–5.
41.
go back to reference Viola GM, Raad II, Rolston KV. Breast tissue expander-related infections: perioperative antimicrobial regimens. Infect Control Hosp Epidemiol. 2014;35:75–81.CrossRefPubMed Viola GM, Raad II, Rolston KV. Breast tissue expander-related infections: perioperative antimicrobial regimens. Infect Control Hosp Epidemiol. 2014;35:75–81.CrossRefPubMed
42.
go back to reference Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR, Guideline for Prevention of Surgical Site Infection. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999;1999(27):97–132.CrossRef Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR, Guideline for Prevention of Surgical Site Infection. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999;1999(27):97–132.CrossRef
43.
go back to reference Feldman EM, Kontoyiannis DP, Sharabi SE, Lee E, Kaufman Y, Heller L. Breast implant infections: is cefazolin enough? Plast Reconstr Surg. 2010;126:779–85.CrossRefPubMed Feldman EM, Kontoyiannis DP, Sharabi SE, Lee E, Kaufman Y, Heller L. Breast implant infections: is cefazolin enough? Plast Reconstr Surg. 2010;126:779–85.CrossRefPubMed
44.
go back to reference Ariyan S, Martin J, Lal A, et al. Antibiotic prophylaxis for preventing surgical-site infection in plastic surgery: an evidence-based consensus conference statement from the American Association of Plastic Surgeons. Plast Reconstr Surg. 2015;135:1723–39.CrossRefPubMed Ariyan S, Martin J, Lal A, et al. Antibiotic prophylaxis for preventing surgical-site infection in plastic surgery: an evidence-based consensus conference statement from the American Association of Plastic Surgeons. Plast Reconstr Surg. 2015;135:1723–39.CrossRefPubMed
45.
go back to reference Phillips BT, Bishawi M, Dagum AB, Khan SU, Bui DT. A systematic review of antibiotic use and infection in breast reconstruction: what is the evidence? Plast Reconstr Surg. 2013;131:1–13.CrossRefPubMed Phillips BT, Bishawi M, Dagum AB, Khan SU, Bui DT. A systematic review of antibiotic use and infection in breast reconstruction: what is the evidence? Plast Reconstr Surg. 2013;131:1–13.CrossRefPubMed
46.
go back to reference Viola GM, Baumann DP, Mohan K, et al. Improving antimicrobial regimens for the treatment of breast tissue expander-related infections. Plast Reconstr Surg Glob Open. 2016;4:e704.CrossRefPubMedPubMedCentral Viola GM, Baumann DP, Mohan K, et al. Improving antimicrobial regimens for the treatment of breast tissue expander-related infections. Plast Reconstr Surg Glob Open. 2016;4:e704.CrossRefPubMedPubMedCentral
47.
go back to reference Viola GM, Selber JC, Crosby M, et al. Salvaging the infected breast tissue expander: a standardized multidisciplinary approach. Plast Reconstr Surg Glob Open. 2016;4:e732.CrossRefPubMedPubMedCentral Viola GM, Selber JC, Crosby M, et al. Salvaging the infected breast tissue expander: a standardized multidisciplinary approach. Plast Reconstr Surg Glob Open. 2016;4:e732.CrossRefPubMedPubMedCentral
48.
go back to reference Cohen JB, Carroll C, Tenenbaum MM, Myckatyn TM. Breast implant-associated infections: the role of the national surgical quality improvement program and the local microbiome. Plast Reconstr Surg. 2015;136:921–9.CrossRefPubMed Cohen JB, Carroll C, Tenenbaum MM, Myckatyn TM. Breast implant-associated infections: the role of the national surgical quality improvement program and the local microbiome. Plast Reconstr Surg. 2015;136:921–9.CrossRefPubMed
49.
go back to reference Weichman KE, Levine SM, Wilson SC, Choi M, Karp NS. Antibiotic selection for the treatment of infectious complications of implant-based breast reconstruction. Ann Plast Surg. 2013;71:140–3.CrossRefPubMed Weichman KE, Levine SM, Wilson SC, Choi M, Karp NS. Antibiotic selection for the treatment of infectious complications of implant-based breast reconstruction. Ann Plast Surg. 2013;71:140–3.CrossRefPubMed
50.
go back to reference Huang SY, Philip A, Richter MD, Gupta S, Lessne ML, Kim CY. Prevention and management of infectious complications of percutaneous interventions. Semin Interv Radiol. 2015;32:78–88.CrossRef Huang SY, Philip A, Richter MD, Gupta S, Lessne ML, Kim CY. Prevention and management of infectious complications of percutaneous interventions. Semin Interv Radiol. 2015;32:78–88.CrossRef
51.
go back to reference Shi S, Xia W, Guo H, Kong H, Zheng S. Unique characteristics of pyogenic liver abscesses of biliary origin. Surgery. 2016;159:1316–24.CrossRefPubMed Shi S, Xia W, Guo H, Kong H, Zheng S. Unique characteristics of pyogenic liver abscesses of biliary origin. Surgery. 2016;159:1316–24.CrossRefPubMed
52.
go back to reference Sun Z, Li G, Ai X, et al. Hepatic and biliary damage after transarterial chemoembolization for malignant hepatic tumors: incidence, diagnosis, treatment, outcome and mechanism. Crit Rev Oncol Hematol. 2011;79:164–74.CrossRefPubMed Sun Z, Li G, Ai X, et al. Hepatic and biliary damage after transarterial chemoembolization for malignant hepatic tumors: incidence, diagnosis, treatment, outcome and mechanism. Crit Rev Oncol Hematol. 2011;79:164–74.CrossRefPubMed
53.
go back to reference Shin JU, Kim KM, Shin SW, et al. A prediction model for liver abscess developing after transarterial chemoembolization in patients with hepatocellular carcinoma. Dig Liver Dis. 2014;46:813–7.CrossRefPubMed Shin JU, Kim KM, Shin SW, et al. A prediction model for liver abscess developing after transarterial chemoembolization in patients with hepatocellular carcinoma. Dig Liver Dis. 2014;46:813–7.CrossRefPubMed
54.
go back to reference Rolston KV, Dholakia N, Rodriguez S, Rubenstein EB. Nature and outcome of febrile episodes in patients with pancreatic and hepatobiliary cancer. Support Care Cancer. 1995;3:414–7.CrossRefPubMed Rolston KV, Dholakia N, Rodriguez S, Rubenstein EB. Nature and outcome of febrile episodes in patients with pancreatic and hepatobiliary cancer. Support Care Cancer. 1995;3:414–7.CrossRefPubMed
55.
go back to reference Xu C, Lv PH, Huang XE, Wang SX, Sun L, Wang FA. Analysis of different ways of drainage for obstructive jaundice caused by hilar cholangiocarcinoma. Asian Pac J Cancer Prev. 2014;15:5617–20.CrossRefPubMed Xu C, Lv PH, Huang XE, Wang SX, Sun L, Wang FA. Analysis of different ways of drainage for obstructive jaundice caused by hilar cholangiocarcinoma. Asian Pac J Cancer Prev. 2014;15:5617–20.CrossRefPubMed
56.
go back to reference Sugiyama G, Okabe Y, Ishida Y, et al. Evaluation of endoscopic biliary stenting for obstructive jaundice caused by hepatocellular carcinoma. World J Gastroenterol. 2014;20:6968–73.CrossRefPubMedPubMedCentral Sugiyama G, Okabe Y, Ishida Y, et al. Evaluation of endoscopic biliary stenting for obstructive jaundice caused by hepatocellular carcinoma. World J Gastroenterol. 2014;20:6968–73.CrossRefPubMedPubMedCentral
57.
go back to reference Schneider J, Hapfelmeier A, Fremd J, et al. Biliary endoprosthesis: a prospective analysis of bacterial colonization and risk factors for sludge formation. PLoS ONE. 2014;9:e110112.CrossRefPubMedPubMedCentral Schneider J, Hapfelmeier A, Fremd J, et al. Biliary endoprosthesis: a prospective analysis of bacterial colonization and risk factors for sludge formation. PLoS ONE. 2014;9:e110112.CrossRefPubMedPubMedCentral
58.
go back to reference Fujii T, Yamada S, Suenaga M, et al. Preoperative internal biliary drainage increases the risk of bile juice infection and pancreatic fistula after pancreatoduodenectomy: a prospective observational study. Pancreas. 2015;44:465–70.CrossRefPubMed Fujii T, Yamada S, Suenaga M, et al. Preoperative internal biliary drainage increases the risk of bile juice infection and pancreatic fistula after pancreatoduodenectomy: a prospective observational study. Pancreas. 2015;44:465–70.CrossRefPubMed
59.
go back to reference Gorschlüter M, Marklein G, Höfling K, et al. Abdominal infections in patients with acute leukaemia: a prospective study applying ultrasonography and microbiology. Br J Haematol. 2002;117:351–8.CrossRefPubMed Gorschlüter M, Marklein G, Höfling K, et al. Abdominal infections in patients with acute leukaemia: a prospective study applying ultrasonography and microbiology. Br J Haematol. 2002;117:351–8.CrossRefPubMed
60.
go back to reference Capria S, Vitolo D, Cartoni C, et al. Neutropenic enterocolitis in acute leukemia: diagnostic and therapeutic dilemma. Ann Hematol. 2004;83:195–7.CrossRefPubMed Capria S, Vitolo D, Cartoni C, et al. Neutropenic enterocolitis in acute leukemia: diagnostic and therapeutic dilemma. Ann Hematol. 2004;83:195–7.CrossRefPubMed
61.
go back to reference Nesher L, Rolston KVI. Neutropenic enterocolitis, a growing concern in the era of widespread use of aggressive chemotherapy. Clin Infect Dis. 2013;56:711–7.CrossRefPubMed Nesher L, Rolston KVI. Neutropenic enterocolitis, a growing concern in the era of widespread use of aggressive chemotherapy. Clin Infect Dis. 2013;56:711–7.CrossRefPubMed
62.
go back to reference Ibrahim NK, Sahin AA, Dubrow RA, et al. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet. 2000;355:281–3.CrossRefPubMed Ibrahim NK, Sahin AA, Dubrow RA, et al. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet. 2000;355:281–3.CrossRefPubMed
63.
go back to reference Kreis W, Petrylak D, Savarese D, Budman D. Colitis and docetaxel-based chemotherapy. Lancet. 2000;355:2164.CrossRefPubMed Kreis W, Petrylak D, Savarese D, Budman D. Colitis and docetaxel-based chemotherapy. Lancet. 2000;355:2164.CrossRefPubMed
64.
go back to reference de Matteis A, Nuzzo F, Rossi E, Landi G, Perrone F. Intestinal side-effects of docetaxel/vinorelbine combination. Lancet. 2000;355:1098–9.CrossRefPubMed de Matteis A, Nuzzo F, Rossi E, Landi G, Perrone F. Intestinal side-effects of docetaxel/vinorelbine combination. Lancet. 2000;355:1098–9.CrossRefPubMed
65.
go back to reference Kirkpatrick ID, Greenberg HM. Gastrointestinal complications in the neutropenic patient: characterization and differentiation with abdominal CT. Radiology. 2003;226:668–74.CrossRefPubMed Kirkpatrick ID, Greenberg HM. Gastrointestinal complications in the neutropenic patient: characterization and differentiation with abdominal CT. Radiology. 2003;226:668–74.CrossRefPubMed
66.
go back to reference Cartoni C, Dragoni F, Micozzi A, et al. Neutropenic enterocolitis in patients with acute leukemia: prognostic significance of bowel wall thickening detected by ultrasonography. J Clin Oncol. 2001;19:756–61.CrossRefPubMed Cartoni C, Dragoni F, Micozzi A, et al. Neutropenic enterocolitis in patients with acute leukemia: prognostic significance of bowel wall thickening detected by ultrasonography. J Clin Oncol. 2001;19:756–61.CrossRefPubMed
67.
go back to reference Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365:1693–703.CrossRefPubMed Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365:1693–703.CrossRefPubMed
68.
go back to reference Emoto M, Kawarabayashi T, Hachisuga MD, Eguchi F, Shirakawa K. Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. Gynecol Oncol. 1996;61:369–72.CrossRefPubMed Emoto M, Kawarabayashi T, Hachisuga MD, Eguchi F, Shirakawa K. Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. Gynecol Oncol. 1996;61:369–72.CrossRefPubMed
69.
go back to reference Allen VA, Manahan KJ, Geisler JP. Recurrent pseudomembranous colitis in an ovarian cancer patient undergoing carboplatin chemotherapy. Case Rep Obstet Gynecol. 2016;2016:7540302.PubMedPubMedCentral Allen VA, Manahan KJ, Geisler JP. Recurrent pseudomembranous colitis in an ovarian cancer patient undergoing carboplatin chemotherapy. Case Rep Obstet Gynecol. 2016;2016:7540302.PubMedPubMedCentral
70.
go back to reference Penziner S, Dubrovskaya Y, Press R, Safdar A. Fidaxomicin therapy in critically ill patients with Clostridium difficile infection. Antimicrob Agents Chemother. 2015;59:1776–81.CrossRefPubMedPubMedCentral Penziner S, Dubrovskaya Y, Press R, Safdar A. Fidaxomicin therapy in critically ill patients with Clostridium difficile infection. Antimicrob Agents Chemother. 2015;59:1776–81.CrossRefPubMedPubMedCentral
71.
go back to reference Cornely OA, Nathwani D, Ivanescu C, Odufowora-Sita O, Retsa P, Odeyemi IA. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother. 2014;69:2892–900.CrossRefPubMed Cornely OA, Nathwani D, Ivanescu C, Odufowora-Sita O, Retsa P, Odeyemi IA. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother. 2014;69:2892–900.CrossRefPubMed
72.
go back to reference Zhanel GG, Walkty AJ, Karlowsky JA. Fidaxomicin: a novel agent for the treatment of Clostridium difficile infection. Can J Infect Dis Med Microbiol. 2015;26:305–12.PubMedPubMedCentral Zhanel GG, Walkty AJ, Karlowsky JA. Fidaxomicin: a novel agent for the treatment of Clostridium difficile infection. Can J Infect Dis Med Microbiol. 2015;26:305–12.PubMedPubMedCentral
73.
go back to reference Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med. 2016;165:609–616. Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med. 2016;165:609–616.
74.
go back to reference Schlick K, Grundbichler M, Auberger J, et al. Cytomegalovirus reactivation and its clinical impact in patients with solid tumors. Infect Agent Cancer. 2015;10:45.CrossRefPubMedPubMedCentral Schlick K, Grundbichler M, Auberger J, et al. Cytomegalovirus reactivation and its clinical impact in patients with solid tumors. Infect Agent Cancer. 2015;10:45.CrossRefPubMedPubMedCentral
75.
go back to reference Torres HA, Kontoyiannis DP, Bodey GP, et al. Gastrointestinal cytomegalovirus disease in patients with cancer: a two decade experience in a tertiary care cancer center. Eur J Cancer. 2005;41:2268–79.CrossRefPubMed Torres HA, Kontoyiannis DP, Bodey GP, et al. Gastrointestinal cytomegalovirus disease in patients with cancer: a two decade experience in a tertiary care cancer center. Eur J Cancer. 2005;41:2268–79.CrossRefPubMed
76.
77.
go back to reference Wasley A, Kruszon-Moran D, Kuhnert W, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis. 2010;202:192–201.CrossRefPubMed Wasley A, Kruszon-Moran D, Kuhnert W, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis. 2010;202:192–201.CrossRefPubMed
78.
go back to reference Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis. 2012;55(Suppl 1):S10–5.CrossRefPubMed Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis. 2012;55(Suppl 1):S10–5.CrossRefPubMed
79.
go back to reference Hwang JP, Somerfield MR, Alston-Johnson DE, et al. Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update. J Clin Oncol. 2015;33:2212–20.CrossRefPubMedPubMedCentral Hwang JP, Somerfield MR, Alston-Johnson DE, et al. Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update. J Clin Oncol. 2015;33:2212–20.CrossRefPubMedPubMedCentral
80.
81.
go back to reference Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57:1–20.PubMed Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57:1–20.PubMed
82.
go back to reference Paul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med. 2016;164:30–40.CrossRefPubMed Paul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med. 2016;164:30–40.CrossRefPubMed
83.
go back to reference Hwang JP, Barbo AG, Perrillo RP. Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases. J Viral Hepat. 2015;22:346–52.CrossRefPubMed Hwang JP, Barbo AG, Perrillo RP. Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases. J Viral Hepat. 2015;22:346–52.CrossRefPubMed
84.
go back to reference Hwang JP, Vierling JM, Zelenetz AD, Lackey SC, Loomba R. Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer. 2012;20:2999–3008.CrossRefPubMedPubMedCentral Hwang JP, Vierling JM, Zelenetz AD, Lackey SC, Loomba R. Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer. 2012;20:2999–3008.CrossRefPubMedPubMedCentral
85.
go back to reference Baden LR, Swaminathan S, Angarone M, et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2016;14:882–913. Baden LR, Swaminathan S, Angarone M, et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2016;14:882–913.
86.
go back to reference Torres HA, Mahale P, Blechacz B, et al. Effect of hepatitis C virus infection in patients with cancer: addressing a neglected population. J Natl Compr Cancer Netw. 2015;13:41–50. Torres HA, Mahale P, Blechacz B, et al. Effect of hepatitis C virus infection in patients with cancer: addressing a neglected population. J Natl Compr Cancer Netw. 2015;13:41–50.
87.
go back to reference Mahale P, Kontoyiannis DP, Chemaly RF, et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol. 2012;57:1177–85.CrossRefPubMed Mahale P, Kontoyiannis DP, Chemaly RF, et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol. 2012;57:1177–85.CrossRefPubMed
89.
go back to reference Lee MH, Yang HI, Yuan Y, L’Italien G, Chen CJ. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol. 2014;20:9270–80.PubMedPubMedCentral Lee MH, Yang HI, Yuan Y, L’Italien G, Chen CJ. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol. 2014;20:9270–80.PubMedPubMedCentral
90.
go back to reference Yazici O, Sendur MA, Aksoy S. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. World J Gastroenterol. 2014;20:6716–24.CrossRefPubMedPubMedCentral Yazici O, Sendur MA, Aksoy S. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. World J Gastroenterol. 2014;20:6716–24.CrossRefPubMedPubMedCentral
91.
go back to reference Butt AA, Wang X, Moore CG. Effect of hepatitis C virus and its treatment on survival. Hepatology. 2009;50:387–92.CrossRefPubMed Butt AA, Wang X, Moore CG. Effect of hepatitis C virus and its treatment on survival. Hepatology. 2009;50:387–92.CrossRefPubMed
92.
go back to reference Mira JA, Rivero-Juárez A, López-Cortés LF, et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis. 2013;56:1646–53.CrossRefPubMed Mira JA, Rivero-Juárez A, López-Cortés LF, et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis. 2013;56:1646–53.CrossRefPubMed
93.
go back to reference Flukes S, Hayne D, Kuan M, Wallace M, McMillan K, Rukin NJ. Retrograde ureteric stent insertion in the management of infected obstructed kidneys. BJU Int. 2015;115(Suppl 5):31–4.CrossRefPubMed Flukes S, Hayne D, Kuan M, Wallace M, McMillan K, Rukin NJ. Retrograde ureteric stent insertion in the management of infected obstructed kidneys. BJU Int. 2015;115(Suppl 5):31–4.CrossRefPubMed
94.
go back to reference Benson AD, Taylor ER, Schwartz BF. Metal ureteral stent for benign and malignant ureteral obstruction. J Urol. 2011;185:2217–22.CrossRefPubMed Benson AD, Taylor ER, Schwartz BF. Metal ureteral stent for benign and malignant ureteral obstruction. J Urol. 2011;185:2217–22.CrossRefPubMed
95.
go back to reference Goldsmith ZG, Wang AJ, Bañez LL, et al. Outcomes of metallic stents for malignant ureteral obstruction. J Urol. 2012;188:851–5.CrossRefPubMed Goldsmith ZG, Wang AJ, Bañez LL, et al. Outcomes of metallic stents for malignant ureteral obstruction. J Urol. 2012;188:851–5.CrossRefPubMed
96.
go back to reference de Naurois J, Novitzky-Basso I, Gill MJ, et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21(Suppl 5):v252–6.CrossRefPubMed de Naurois J, Novitzky-Basso I, Gill MJ, et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21(Suppl 5):v252–6.CrossRefPubMed
Metadata
Title
Infections in Cancer Patients with Solid Tumors: A Review
Author
Kenneth V. I. Rolston
Publication date
01-03-2017
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy / Issue 1/2017
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-017-0146-1

Other articles of this Issue 1/2017

Infectious Diseases and Therapy 1/2017 Go to the issue